Nivolumab treatment beyond RECIST‐defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial

BACKGROUND: Response patterns with immune checkpoint inhibitors may be different from those with chemotherapy. Therefore, assessment of response to immunotherapy with the Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1, could result in premature treatment termination. The randomiz...

Descripción completa

Detalles Bibliográficos
Autores principales: Haddad, Robert, Concha‐Benavente, Fernando, Blumenschein, George, Fayette, Jerome, Guigay, Joel, Colevas, A. Dimitrios, Licitra, Lisa, Kasper, Stefan, Vokes, Everett E., Worden, Francis, Saba, Nabil F., Tahara, Makoto, Jayaprakash, Vijayvel, Lynch, Mark, Li, Li, Gillison, Maura L., Harrington, Kevin J., Ferris, Robert L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6771504/
https://www.ncbi.nlm.nih.gov/pubmed/31246283
http://dx.doi.org/10.1002/cncr.32190

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6771504/
https://www.ncbi.nlm.nih.gov/pubmed/31246283
http://dx.doi.org/10.1002/cncr.32190

Ejemplares similares